2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
June 13th 2022
Heinz Gisslinger, MD, discusses the 6-year event-free survival data from the phase 3 PROUD-PV and CONTI-PV trials.
December 6th 2016
Heinz Gisslinger, MD, Medical University of Vienna, discusses the phase III PROUD-PV study, which evaluated ropeginterferon alfa-2b (P1101) for the treatment of polycythemia vera (PV) during the American Society of Hematology (ASH) Annual Meeting.